 Risha Gidwani
Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicare | 9 | 2022 | 773 | 3.330 |
Why?
| | Deductibles and Coinsurance | 2 | 2025 | 13 | 1.830 |
Why?
| | Neoplasms | 10 | 2023 | 2671 | 1.520 |
Why?
| | Quality of Health Care | 4 | 2020 | 642 | 1.290 |
Why?
| | Hospice Care | 4 | 2019 | 202 | 1.170 |
Why?
| | Insurance, Health | 3 | 2025 | 283 | 1.140 |
Why?
| | Terminal Care | 4 | 2020 | 232 | 1.120 |
Why?
| | Lumbar Vertebrae | 4 | 2016 | 246 | 1.070 |
Why?
| | Oncologists | 2 | 2018 | 38 | 1.060 |
Why?
| | Veterans | 8 | 2020 | 1476 | 1.010 |
Why?
| | Ambulatory Care | 2 | 2020 | 546 | 1.000 |
Why?
| | United States | 25 | 2025 | 14841 | 0.980 |
Why?
| | Health Status | 2 | 2025 | 792 | 0.970 |
Why?
| | United States Department of Veterans Affairs | 7 | 2020 | 678 | 0.960 |
Why?
| | Hepatitis C, Chronic | 2 | 2019 | 164 | 0.930 |
Why?
| | Hospitals, Veterans | 5 | 2020 | 252 | 0.920 |
Why?
| | Cost Sharing | 1 | 2024 | 15 | 0.900 |
Why?
| | Telemedicine | 2 | 2024 | 862 | 0.890 |
Why?
| | Insurance, Health, Reimbursement | 2 | 2015 | 99 | 0.890 |
Why?
| | Health Care Reform | 2 | 2015 | 107 | 0.870 |
Why?
| | Financial Management | 1 | 2023 | 18 | 0.850 |
Why?
| | Venous Thrombosis | 2 | 2015 | 190 | 0.800 |
Why?
| | Risk Adjustment | 2 | 2020 | 78 | 0.790 |
Why?
| | Patient Acceptance of Health Care | 3 | 2024 | 806 | 0.790 |
Why?
| | Pulmonary Embolism | 2 | 2015 | 226 | 0.780 |
Why?
| | Medical Overuse | 3 | 2016 | 30 | 0.740 |
Why?
| | Chronic Disease | 4 | 2025 | 1793 | 0.720 |
Why?
| | Veterans Health | 2 | 2020 | 186 | 0.700 |
Why?
| | Guideline Adherence | 1 | 2025 | 556 | 0.670 |
Why?
| | Hospitalization | 4 | 2020 | 2199 | 0.660 |
Why?
| | Eligibility Determination | 1 | 2020 | 65 | 0.660 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 213 | 0.650 |
Why?
| | Aged | 21 | 2025 | 23961 | 0.650 |
Why?
| | Fee-for-Service Plans | 1 | 2019 | 88 | 0.610 |
Why?
| | Breast Neoplasms | 2 | 2021 | 2253 | 0.610 |
Why?
| | Comorbidity | 2 | 2021 | 1622 | 0.600 |
Why?
| | Patient Admission | 1 | 2020 | 197 | 0.580 |
Why?
| | Public Health | 1 | 2023 | 588 | 0.570 |
Why?
| | Medicare Part C | 1 | 2018 | 31 | 0.560 |
Why?
| | Cost-Benefit Analysis | 5 | 2025 | 591 | 0.550 |
Why?
| | Cancer Survivors | 1 | 2022 | 285 | 0.550 |
Why?
| | Low Back Pain | 2 | 2016 | 108 | 0.550 |
Why?
| | Humans | 42 | 2025 | 137585 | 0.540 |
Why?
| | Liver Cirrhosis | 1 | 2019 | 316 | 0.520 |
Why?
| | Female | 29 | 2025 | 73304 | 0.520 |
Why?
| | Length of Stay | 2 | 2019 | 1215 | 0.520 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1050 | 0.510 |
Why?
| | Vaccines | 1 | 2022 | 406 | 0.510 |
Why?
| | Patient Care Management | 1 | 2016 | 57 | 0.510 |
Why?
| | Efficiency, Organizational | 1 | 2017 | 140 | 0.510 |
Why?
| | Menorrhagia | 2 | 2013 | 22 | 0.510 |
Why?
| | Retrospective Studies | 13 | 2023 | 15657 | 0.500 |
Why?
| | Palliative Care | 4 | 2017 | 758 | 0.500 |
Why?
| | Intrauterine Devices, Medicated | 2 | 2013 | 29 | 0.500 |
Why?
| | Decision Making | 2 | 2020 | 900 | 0.500 |
Why?
| | Physicians, Family | 1 | 2017 | 201 | 0.490 |
Why?
| | Documentation | 1 | 2017 | 194 | 0.480 |
Why?
| | Middle Aged | 19 | 2025 | 33479 | 0.470 |
Why?
| | Job Satisfaction | 1 | 2017 | 218 | 0.470 |
Why?
| | Consumer Health Information | 1 | 2015 | 47 | 0.460 |
Why?
| | Intensive Care Units | 2 | 2019 | 827 | 0.440 |
Why?
| | Male | 24 | 2025 | 67762 | 0.440 |
Why?
| | Proline | 1 | 2014 | 79 | 0.440 |
Why?
| | Endometrial Ablation Techniques | 1 | 2013 | 2 | 0.420 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2014 | 135 | 0.420 |
Why?
| | Menstruation | 1 | 2013 | 43 | 0.410 |
Why?
| | Patient Satisfaction | 1 | 2017 | 660 | 0.410 |
Why?
| | Family Practice | 1 | 2017 | 464 | 0.400 |
Why?
| | Antiviral Agents | 2 | 2019 | 744 | 0.400 |
Why?
| | Emergency Service, Hospital | 3 | 2015 | 2069 | 0.400 |
Why?
| | Oligopeptides | 1 | 2014 | 271 | 0.400 |
Why?
| | Attitude of Health Personnel | 3 | 2018 | 1171 | 0.390 |
Why?
| | Spinal Fusion | 1 | 2014 | 251 | 0.350 |
Why?
| | AIDS Serodiagnosis | 1 | 2011 | 24 | 0.350 |
Why?
| | Internet | 1 | 2015 | 655 | 0.340 |
Why?
| | Azacitidine | 1 | 2011 | 140 | 0.340 |
Why?
| | Myelodysplastic Syndromes | 1 | 2011 | 135 | 0.320 |
Why?
| | Enzyme Inhibitors | 1 | 2011 | 840 | 0.290 |
Why?
| | Hospices | 3 | 2018 | 87 | 0.280 |
Why?
| | Disease Progression | 1 | 2015 | 2757 | 0.270 |
Why?
| | Neoplasm Staging | 2 | 2021 | 1389 | 0.270 |
Why?
| | Administrative Claims, Healthcare | 2 | 2018 | 26 | 0.270 |
Why?
| | Magnetic Resonance Imaging | 2 | 2016 | 3566 | 0.260 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1313 | 0.260 |
Why?
| | California | 3 | 2025 | 431 | 0.260 |
Why?
| | Quality-Adjusted Life Years | 2 | 2025 | 113 | 0.250 |
Why?
| | Adult | 11 | 2025 | 37929 | 0.250 |
Why?
| | Primary Health Care | 1 | 2016 | 1738 | 0.250 |
Why?
| | Taxes | 1 | 2025 | 14 | 0.240 |
Why?
| | Mass Screening | 2 | 2011 | 1287 | 0.240 |
Why?
| | Hepacivirus | 2 | 2019 | 261 | 0.240 |
Why?
| | Carbonated Beverages | 1 | 2025 | 16 | 0.240 |
Why?
| | Logistic Models | 2 | 2023 | 2074 | 0.220 |
Why?
| | Hospitals, Private | 1 | 2023 | 12 | 0.220 |
Why?
| | Interviews as Topic | 2 | 2018 | 786 | 0.220 |
Why?
| | Pandemics | 2 | 2023 | 1639 | 0.210 |
Why?
| | Levonorgestrel | 2 | 2013 | 38 | 0.200 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7635 | 0.200 |
Why?
| | Young Adult | 6 | 2025 | 13209 | 0.190 |
Why?
| | Medically Uninsured | 1 | 2022 | 130 | 0.180 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2022 | 103 | 0.180 |
Why?
| | Health Status Disparities | 1 | 2024 | 289 | 0.180 |
Why?
| | Privatization | 1 | 2020 | 7 | 0.170 |
Why?
| | Insurance Coverage | 1 | 2022 | 230 | 0.170 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2844 | 0.170 |
Why?
| | Qualitative Research | 2 | 2018 | 1386 | 0.160 |
Why?
| | Probability | 1 | 2020 | 304 | 0.160 |
Why?
| | Financing, Personal | 1 | 2019 | 26 | 0.160 |
Why?
| | HIV Infections | 2 | 2011 | 2836 | 0.150 |
Why?
| | Publishing | 1 | 2020 | 147 | 0.150 |
Why?
| | Databases, Factual | 2 | 2014 | 1357 | 0.150 |
Why?
| | Medicaid | 1 | 2023 | 435 | 0.150 |
Why?
| | Needs Assessment | 1 | 2020 | 376 | 0.150 |
Why?
| | Hospitals | 1 | 2023 | 691 | 0.140 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1266 | 0.140 |
Why?
| | Health Expenditures | 1 | 2019 | 189 | 0.140 |
Why?
| | Adolescent | 4 | 2025 | 21513 | 0.140 |
Why?
| | Blood Pressure | 1 | 2024 | 1786 | 0.130 |
Why?
| | Cost of Illness | 1 | 2019 | 308 | 0.130 |
Why?
| | Bereavement | 1 | 2017 | 53 | 0.130 |
Why?
| | Alcohol Deterrents | 1 | 2016 | 18 | 0.130 |
Why?
| | Utilization Review | 1 | 2016 | 36 | 0.130 |
Why?
| | Drug Therapy | 1 | 2015 | 85 | 0.120 |
Why?
| | Alcohol-Related Disorders | 1 | 2016 | 122 | 0.120 |
Why?
| | Hypertension | 1 | 2024 | 1295 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 322 | 0.120 |
Why?
| | Publications | 1 | 2015 | 47 | 0.110 |
Why?
| | Radiotherapy | 1 | 2015 | 201 | 0.110 |
Why?
| | Genotyping Techniques | 1 | 2014 | 75 | 0.110 |
Why?
| | Cell Phone | 1 | 2015 | 76 | 0.110 |
Why?
| | Medical Informatics | 1 | 2015 | 101 | 0.110 |
Why?
| | Policy Making | 1 | 2014 | 98 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2016 | 283 | 0.110 |
Why?
| | Ribavirin | 1 | 2014 | 91 | 0.110 |
Why?
| | Confidence Intervals | 1 | 2014 | 329 | 0.110 |
Why?
| | Cohort Studies | 2 | 2023 | 5742 | 0.110 |
Why?
| | Drug Utilization | 1 | 2014 | 169 | 0.110 |
Why?
| | Thoracic Vertebrae | 1 | 2014 | 77 | 0.110 |
Why?
| | Danazol | 1 | 2013 | 1 | 0.110 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2016 | 611 | 0.110 |
Why?
| | Interferon-alpha | 1 | 2014 | 198 | 0.100 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 548 | 0.100 |
Why?
| | Interferons | 1 | 2014 | 202 | 0.100 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2022 | 1329 | 0.100 |
Why?
| | Parents | 1 | 2022 | 1347 | 0.100 |
Why?
| | Odds Ratio | 1 | 2016 | 1070 | 0.100 |
Why?
| | Interleukins | 1 | 2014 | 250 | 0.100 |
Why?
| | Progestins | 1 | 2013 | 79 | 0.100 |
Why?
| | Family | 1 | 2017 | 671 | 0.100 |
Why?
| | Respiration, Artificial | 1 | 2017 | 645 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2020 | 10811 | 0.100 |
Why?
| | Patient Compliance | 1 | 2016 | 581 | 0.100 |
Why?
| | Quality Improvement | 1 | 2020 | 1178 | 0.090 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2014 | 177 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2111 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1066 | 0.090 |
Why?
| | Obesity | 1 | 2025 | 2992 | 0.090 |
Why?
| | Reoperation | 1 | 2014 | 573 | 0.090 |
Why?
| | Bayes Theorem | 1 | 2013 | 405 | 0.090 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5472 | 0.090 |
Why?
| | Communication | 1 | 2016 | 879 | 0.090 |
Why?
| | Surveys and Questionnaires | 3 | 2023 | 5778 | 0.080 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 363 | 0.080 |
Why?
| | Quality of Life | 2 | 2018 | 2892 | 0.070 |
Why?
| | Community-Based Participatory Research | 1 | 2010 | 162 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2016 | 1069 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1081 | 0.070 |
Why?
| | Incidence | 1 | 2014 | 2804 | 0.070 |
Why?
| | Health Care Costs | 1 | 2011 | 398 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1477 | 0.070 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2526 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2014 | 3556 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2129 | 0.060 |
Why?
| | Risk Assessment | 1 | 2014 | 3457 | 0.060 |
Why?
| | Health Surveys | 1 | 2025 | 514 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2010 | 986 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2014 | 2654 | 0.050 |
Why?
| | Brazil | 1 | 2022 | 167 | 0.050 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 447 | 0.040 |
Why?
| | Prevalence | 1 | 2025 | 2734 | 0.040 |
Why?
| | Disulfiram | 1 | 2016 | 14 | 0.030 |
Why?
| | Consumer Behavior | 1 | 2017 | 71 | 0.030 |
Why?
| | Taurine | 1 | 2016 | 46 | 0.030 |
Why?
| | Fructose | 1 | 2016 | 112 | 0.030 |
Why?
| | Naltrexone | 1 | 2016 | 97 | 0.030 |
Why?
| | Nursing Homes | 1 | 2017 | 181 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 2015 | 156 | 0.030 |
Why?
| | Colonic Neoplasms | 1 | 2015 | 258 | 0.030 |
Why?
| | Pregnancy, Unplanned | 1 | 2013 | 48 | 0.020 |
Why?
| | Models, Economic | 1 | 2013 | 58 | 0.020 |
Why?
| | Hysterectomy | 1 | 2013 | 129 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1946 | 0.020 |
Why?
| | Head and Neck Neoplasms | 1 | 2015 | 606 | 0.020 |
Why?
| | Risk Factors | 1 | 2024 | 10388 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2010 | 134 | 0.020 |
Why?
| | Liver Neoplasms | 1 | 2015 | 786 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2010 | 271 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3284 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 1043 | 0.020 |
Why?
| | Program Evaluation | 1 | 2010 | 898 | 0.020 |
Why?
| | Pregnancy | 1 | 2013 | 6763 | 0.010 |
Why?
|
|
Gidwani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|